Joelle Fathi is on a mission to make a meaningful contribution and transform healthcare to make it more equitable. It’s an ambitious goal that GO2 for Lung Cancer’s chief healthcare delivery officer believes is essential to increase lung cancer [...]
Question: My doctors have determined that my lung cancer is progressing on its current targeted therapy and want to do another biopsy. Why would I need another biopsy since we already know the biomarker type? If I do need [...]
GO2 for Lung Cancer recognized Dr. Rafael Rosell at the 23rd International Lung Cancer Congress for his global contributions to oncology, particularly in the field of non-small-cell lung cancer (San Carlos, CA and Washington, DC) – GO2 for Lung [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
Author: Andrew Ciupek, PhD, Senior Manager of Clinical Research Due to the increasing number of approved targeted therapies for the treatment of lung cancer, clinical guidelines recommend that every patient receive comprehensive biomarker testing. Despite the importance of comprehensive [...]
If there is one thing we learned last year, it is that we are stronger together. Despite the ongoing pandemic in 2021, we rallied our community to help transform survivorship. We persevered and expanded vital services to meet the [...]
National advocacy organizations, including GO2 for Lung Cancer, have been advocating for legislative policies to increase and improve access to biomarker testing. Those efforts are increasing, especially at the state level, as legislatures take up biomarker testing bills. Educating [...]
Sarina Logan is 41 and was diagnosed with non-small cell lung cancer (NSCLC) in 2018. Thanks to the urging of family friend and GO2 for Lung Cancer Co-founder Bonnie Addario, Logan had comprehensive biomarker testing. The finding that her [...]
Authors: Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer and Jacinta R. Wiens, PhD, Director of Lung Cancer Registry, GO2 for Lung Cancer The World Conference on Lung Cancer (WCLC) highlighted many up-and-coming treatments for [...]
Stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated in recent years by the genetic mutation, or biomarker. Patients received either chemotherapy, immunotherapy, a combination of the two, or a personalized targeted therapy depending on the [...]